Fig. 1 · Structure

Documents & Downloads

Imidapril

Cat. No. A11867 CAS 89371-37-9
Imidapril (Tanatril) is an inhibitor of angiotensin converting enzyme (ACE).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Imidapril Research Summary

This section summarizes 4 in vivo studies of Imidapril from 3 published references. In vivo models include db/db mice; streptozotocin- (STZ-) treated CD-1 mice.

Imidapril In Vivo Studies

In db/db mice, Imidapril administered in drinking water significantly increased urine AcSDKP concentration compared with vehicle alone. In streptozotocin-treated CD-1 mice, Imidapril administered in drinking water partially decreased interstitial fibrosis compared with untreated diabetic mice. In pure strain male NMRI mice bearing MAC16 tumours, oral Imidapril administered by gavage attenuated the development of weight loss compared with water controls, with a dose-related effect. In another study in db/db mice, Imidapril administered in drinking water significantly suppressed glomerular mesangial area expansion compared with no treatment. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Imidapril increases urinary AcSDKP in db/db mice

Animal study · db/db mice [1]

In db/db mice, Imidapril administered in drinking water significantly increased urine AcSDKP concentration compared with vehicle alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
urine AcSDKP concentrationReported result 2.5 mg/kg BW/day: Imidapril treatment significantly increased the urine AcSDKP concentration compared to vehicle alone in the db/db mice.[1]

Conditions shared by the study groups

Route
in the drinking water
Treatment course
At 20 weeks of age; euthanized at 24 weeks of age
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Imidapril 2.5 mg/kg BW/dayvehicle alone2.5 mg/kg BW/day: Imidapril treatment significantly increased the urine AcSDKP concentration compared to vehicle alone in the db/db mice.[1]
Imidapril 2.5 mg/kg BW/day
Model: db/db mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Imidapril

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Animal Experiments (S11, S12, S13); 3. Results > 3.1. Elevation of Both Plasma and Urine AcSDKP Levels after the Oral Administration of AcSDKP (S54)

urine AcSDKP concentration: urine AcSDKP concentration; comparator: vehicle alone — 2. Materials and Methods > 2.2. Animal Experiments (S11); 3. Results > 3.1. Elevation of Both Plasma and Urine AcSDKP Levels after the Oral Administration of AcSDKP (S54)

Imidapril 2.5 mg/kg BW/day · 2. Materials and Methods > 2.2. Animal Experiments (S11, S12, S13); 3. Results > 3.1. Elevation of Both Plasma and Urine AcSDKP Levels after the Oral Administration of AcSDKP (S54)

Imidapril partially decreases interstitial fibrosis in diabetic mice

Animal study · streptozotocin- (STZ-) treated CD-1 mice [2]

In streptozotocin-treated CD-1 mice, Imidapril administered in drinking water partially decreased interstitial fibrosis compared with untreated diabetic mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
relative area of fibrosisReported result 2.5 mg/kg BW/day: imidapril partially decreased interstitial fibrosis.[2]

Conditions shared by the study groups

Route
in drinking water
Treatment course
Sixteen weeks after the induction of diabetes; euthanized 24 weeks after the induction of diabetes
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Imidapril 2.5 mg/kg BW/dayuntreated diabetic mice2.5 mg/kg BW/day: imidapril partially decreased interstitial fibrosis.[2]
Imidapril 2.5 mg/kg BW/day
Model: streptozotocin- (STZ-) treated CD-1 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Imidapril

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Animal Experiments (S10, S12, S14, S15, S16); 3. Results > 3.1. Antifibrotic Effect of AcSDKP on the Top of ACE-I (S58); Figure 2 legend (S99)

relative area of fibrosis: relative area of fibrosis; comparator: untreated diabetic mice — 2. Materials and Methods > 2.2. Animal Experiments (S14); 3. Results > 3.1. Antifibrotic Effect of AcSDKP on the Top of ACE-I (S58); Figure 2 legend (S99)

Imidapril 2.5 mg/kg BW/day · 2. Materials and Methods > 2.2. Animal Experiments (S14, S15, S16); 3. Results > 3.1. Antifibrotic Effect of AcSDKP on the Top of ACE-I (S58)

Imidapril attenuates weight loss in tumour-bearing mice

Animal study · Pure strain male NMRI mice; MAC16 tumour; n=10 initially [3]

At a dose level of 30 mg kg−1, imidapril attenuated the development of weight loss. The effect was dose related and was not seen with lower dose levels (3 mg kg−1). The shapes of the curves were significantly different (P<0.001).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
body weightReported result At a dose level of 30 mg kg−1, imidapril attenuated the development of weight loss; the shapes of the curves were significantly different (P<0.001). The effect was dose related and was not seen with lower dose levels (3 mg kg−1).[3]

Conditions shared by the study groups

Route
orally three times daily by gavage
Treatment course
three times daily
Vehicle
water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Imidapril 10 mg kg−1; orally three times daily by gavagewater controlsAt a dose level of 30 mg kg−1, imidapril attenuated the development of weight loss; the shapes of the curves were significantly different (P<0.001). The effect was dose related and was not seen with lower dose levels (3 mg kg−1).[3]
Imidapril 10 mg kg−1; orally three times daily by gavage
Model: Pure strain male NMRI mice; MAC16 tumour; n=10 initially
Methods and source locations

Compound reported in the paper: Imidapril

Evidence for Imidapril as the hydrochloride form reported in the paper, not the free base/neutral form supplied as A11867; no salt equivalence, dose conversion or lot validation.

MATERIALS AND METHODS > Animals (S10, S12); RESULTS (S65, S66); Figure 8 legend (S93, S94, S95, S96)

body weight: body weight; comparator: water controls — RESULTS (S65, S66); Figure 8 legend (S93, S96)

Imidapril 10 mg kg−1; orally three times daily by gavage · MATERIALS AND METHODS > Animals (S12); RESULTS (S65, S66); Figure 8 legend (S94, S96)

Imidapril suppresses glomerular mesangial expansion in db/db mice

Animal study · db/db mice [1]

In db/db mice, Imidapril administered in drinking water significantly suppressed glomerular mesangial area expansion compared with no treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Morphometric analyses for mesangial expansionReported result Imidapril [2.5 mg/kg BW/day]: significant suppression of glomerular mesangial area expansion.[1]

Conditions shared by the study groups

Route
in the drinking water
Treatment course
At 20 weeks of age; At 24 weeks of age, all mice were euthanized
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Imidapril 2.5 mg/kg BW/dayno treatmentImidapril [2.5 mg/kg BW/day]: significant suppression of glomerular mesangial area expansion.[1]
Imidapril 2.5 mg/kg BW/day
Model: db/db mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Imidapril

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Animal Experiments (S11, S12); 3. Results > 3.2. A Higher Level of AcSDKP was Associated with Antifibrotic Effects in the Kidney (S75); Figure 4 legend (S126, S128, S130)

Morphometric analyses for mesangial expansion: Morphometric analyses for mesangial expansion; comparator: no treatment — 2. Materials and Methods > 2.2. Animal Experiments (S11); 3. Results > 3.2. A Higher Level of AcSDKP was Associated with Antifibrotic Effects in the Kidney (S75); Figure 4 legend (S130)

Imidapril 2.5 mg/kg BW/day · 2. Materials and Methods > 2.2. Animal Experiments (S11, S12); 3. Results > 3.2. A Higher Level of AcSDKP was Associated with Antifibrotic Effects in the Kidney (S75); Figure 4 legend (S126, S128)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 89371-37-9
Formula C20H27N3O6
Molecular Weight 405.44
Synonyms Tanatril
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 76 mg/mL (171.98 mM)
Water 46 mg/mL (104.09 mM)
Ethanol 25 mg/mL (56.57 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Imidapril Research References

  1. [1] Nitta K, Shi S, Nagai T, et al. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen. Biomed Res Int (2016). PMID: 27088094 DOI: 10.1155/2016/9172157 Source material
  2. [2] Nagai T, Kanasaki M, Srivastava SP, et al. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. Biomed Res Int (2014). PMID: 24783220 DOI: 10.1155/2014/696475 Source material
  3. [3] Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer (2005). PMID: 16052213 DOI: 10.1038/sj.bjc.6602725 Source material

Added to your cart

View Cart Checkout
Loading...